Form 4: Dexcom Chief Legal Officer Sells Shares Under Pre-Arranged Trading Plan

Dexcom's EVP and Chief Legal Officer, Michael Jon Brown, sold 500 shares of common stock for $82.8 per share on June 16, 2025, as part of a pre-established 10b5-1 trading plan.

Summary

• Michael Jon Brown, Dexcom Inc.'s EVP and Chief Legal Officer, reported the sale of 500 shares of DXCM common stock.
• The transaction occurred on June 16, 2025, at a price of $82.8 per share.
• The sale was executed under a Rule 10b5-1 trading plan, which Mr. Brown adopted on February 21, 2025, designed for the orderly disposition of his shares.
• Following this transaction, Mr. Brown beneficially owns 95,102 shares of Dexcom common stock.
• This remaining beneficial ownership includes 86,490 unvested restricted stock units (RSUs) with various vesting schedules extending through March 8, 2028.
• A Power of Attorney was granted by Mike Brown on May 12, 2025, to Jereme Sylvain, Christophe Cantenot, and Stephanie Fong, authorizing them to prepare and file SEC documents on his behalf.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale of shares by an insider, while a reduction in direct ownership, was conducted under a pre-arranged 10b5-1 plan, which is a common and expected practice for executives managing their equity holdings and is not typically indicative of negative sentiment towards the company's future prospects.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled, non-discretionary transaction rather than a reactive sale.

Negatives

• Michael Jon Brown, EVP and Chief Legal Officer, reduced his direct beneficial ownership of Dexcom common stock by 500 shares.

Risks

• The Power of Attorney explicitly states that the undersigned (Michael Jon Brown) remains solely responsible for compliance with obligations under Section 13 or Section 16 of the Exchange Act, including reporting requirements and potential disgorgement of profits under Section 16(b), despite delegating filing authority.

Future Outlook

NA

Management Comments

• "The undersigned hereby makes, constitutes and appoints each of Jereme Sylvain, Christophe Cantenot, and Stephanie Fong, and any delegee thereof, or either of them or a delegee acting singly, and with full power of substitution, re-substitution and delegation, the undersigneds true and lawful attorney in fact."
• "This Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information."
• "Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigneds responsibility to comply with the requirements of Section 13 or Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act."
• "This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigneds obligations under Section 13 or Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 13 or Section 16 of the Exchange Act."

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape within the medical device or continuous glucose monitoring (CGM) sector. Insider sales under 10b5-1 plans are common and generally not indicative of specific industry-wide shifts.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by an executive under a 10b5-1 plan is generally not considered a significant signal for shareholders, as it's a pre-planned liquidity event rather than a discretionary sale based on new information.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Continued vesting of 86,490 unvested restricted stock units through various dates up to March 8, 2028.
• Ongoing compliance by Michael Jon Brown with Section 13 and Section 16 of the Securities Exchange Act of 1934, including future reporting requirements for changes in beneficial ownership.

Key Dates

Keywords

Dexcom, DXCM, Insider Trading, Form 4, 10b5-1 Plan, Stock Sale, Executive Compensation, Restricted Stock Units, Corporate Governance, SEC Filing